Register for updates

 
 

Medicine & Health
RSS Feed
DNA Delivery Technology Joins Battle Against Drug-Resistant Bacteria
Monday, June 19, 2017 9:20:00 AM

New tool is major milestone against lethal condition, TAU researchers say

Antimicrobial resistance is one of the biggest threats to global health, affecting anyone, at any age, in any country, according to the World Health Organization. Currently, 700,000 deaths each year are attributed to antimicrobial resistance, a figure which could increase to 10 million a year by 2050 save further intervention.

New breakthrough technology from Tel Aviv University facilitates DNA delivery into drug-resistant bacterial pathogens, enabling their manipulation. The research expands the range of bacteriophages, which are the primary tool for introducing DNA into pathogenic bacteria to neutralize their lethal activity. A single type of bacteriophage can be adapted to a wide range of bacteria, an innovation which will likely accelerate the development of potential drugs based on this principle.

Prof. Udi Qimron of the Department of Clinical Microbiology and Immunology at TAU's Sackler Faculty of Medicine led the research team, which also included Dr. Ido Yosef, Dr. Moran Goren, Rea Globus and Shahar Molshanski, all of Prof. Qimron's lab. The study was recently published in Molecular Cell and featured on its cover.

For the research, the team genetically engineered bacteriophages to contain the desired DNA rather than their own genome. They also designed combinations of nanoparticles from different bacteriophages, resulting in hybrids that are able to recognize new bacteria, including pathogenic bacteria. The researchers further used directed evolution to select hybrid particles able to transfer DNA with optimal efficiency.

"DNA manipulation of pathogens includes sensitization to antibiotics, killing of pathogens, disabling pathogens' virulence factors and more," Prof. Qimron said. "We've developed a technology that significantly expands DNA delivery into bacterial pathogens. This may indeed be a milestone, because it opens up many opportunities for DNA manipulations of bacteria that were impossible to accomplish before.

"This could pave the way to changing the human microbiome — the combined genetic material of the microorganisms in humans — by replacing virulent bacteria with a-virulent bacteria and replacing antibiotic-resistant bacteria with antibiotic-sensitive bacteria, as well as changing environmental pathogens," Prof. Qimron continued.

"We have applied for a patent on this technology and are developing products that would use this technology to deliver DNA into bacterial pathogens, rendering them a-virulent and sensitive to antibiotics," Prof. Qimron said.

The research has been granted $700,000 from the Momentum Fund, a unique $24,000,000 fund established by Ramot, Tel Aviv University's business engagement center. This funding enables the advanced development of this technology within TAU laboratories. The Momentum Fund invests in promising breakthrough technologies in a wide range of fields, including pharmaceuticals, healthcare, high-tech and the physical sciences. Tata Group is the lead investor of the Momentum Fund. Singapore-based Temaske is another key investor.




Latest News

Marine Vessels are Unsuspecting Hosts of Invasive Species

Half of the ships passing along the Mediterranean coast of Israel carry damaging ascidians, TAU researchers say.

Inauguration of Steinhardt Museum of Natural History Celebrated at TAU on June 26

Historic event held in presence of philanthropist Michael Steinhardt and family, TAU governors, board members and faculty.

Baxter, Ramot at TAU and Tel Aviv Sourasky Medical Center Partner to Bring New Surgical Innovations Worldwide

Agreements will explore potential applications of promising early-stage research in areas of unmet need.

3,000-Year-Old Textiles Are Earliest Evidence of Chemical Dyeing in The Levant

Discovery provides insight into society and copper production in the Timna region at the time of David and Solomon, TAU researchers say.

Zuckerman Scholar Launches State-of-the-Art Laser Laboratory at TAU

Dr. Ishay Pomerantz hopes to lower the cost and size of particle accelerators for more practical social applications.

The Brain Mechanism Behind Multitasking

The brief reactivation of a learned memory can block interference from competing tasks, TAU researchers say.

DNA Delivery Technology Joins Battle Against Drug-Resistant Bacteria

New tool is major milestone against lethal condition, TAU researchers say.

Cardiac Stem Cells from Heart Disease Patients May Be Harmful

TAU researchers discover molecular pathway involved in toxic interaction between host cells and immune system.

Multispectral Imaging Reveals Ancient Hebrew Inscription Undetected for Over 50 Years

Military correspondence from the First Temple period discovered on reverse side of well-studied artifact at The Israel Museum, TAU researchers say.

Earliest Human Impact on the Environment Took Place 11,500 Years Ago

The earliest geological indication of humans' impact on the environment discovered in the Dead Sea, TAU researchers say.

IDEAS Immersion Program to Host Nine Female Entrepreneurs from TAU

Acceleration program partners with Cross Campus and Google to help budding women entrepreneurs incubate startups.

Prof. Jacob A. Frenkel Elected to Second Term as Chairman of TAU's Board of Governors

Internationally-acclaimed economist will continue to "greatly contribute to the further development of Tel Aviv University," said TAU President Prof. Yossi Klafter.

Solving the Riddle of the Snow Globe

TAU research explains the process of sedimentation in natural and industrial contexts.

contentSecondary
c

© 2017 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University